Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Multiple sclerosis patients to benefit from new drug
November 27, 2013
Thanks in part to research by
Dr. Mark Freedman
and his team, certain multiple sclerosis (MS) patients can now take a simple daily pill to limit disease flare-ups and delay physical disability. Previous first-line therapies were only available as injections, which were difficult (or even impossible) for some patients to manage. Dr. Freedman has worked with Sanofi-Genzyme for more than a decade to conduct clinical trials of the new pill, called teriflunomide, which Health Canada recently approved for treatment of relapsing-remitting MS. Dr. Freedman noted that the approval is “an important advancement for the MS community and may help improve quality of life for people living with this debilitating disease.”
See
news release
for details.
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. www.ohri.ca
Media contact
Jennifer Ganton
Director, Communications and Public Relations
Ottawa Hospital Research Institute
613-798-5555 x 73325
613-614-5253 (cell)
jganton@ohri.ca